EllisLevineMD

PubMed

• 2 citations
  Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
  Shipra Gandhi, Mateusz Opyrchal, Melissa J Grimm, Ronald T Slomba, Kathleen M Kokolus, Agnieszka Witkiewicz, Kristopher Attwood, Adrienne Groman, Lauren Williams, Mary...> ;Journal for Immunotherapy of Cancer. 2023 Nov 1
• 2 citations
  Determinants of response to CDK4/6 inhibitors in the real-world setting.
  Agnieszka K Witkiewicz, Emily Schultz, Jianxin Wang, Deanna Hamilton, Ellis Levine, Tracey O'Connor, Erik S Knudsen> ;NPJ Precision Oncology. 2023 Sep 13
• 1 citations
  Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters.
  Ahmad Shariftabrizi, Shalin Kothari, Saby George, Kristopher Attwood, Ellis Levine, Dominick Lamonica> ;The Oncologist. 2023 Mar 17
• 1 citations
  Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort...
  Adith Abraham, Carlos H Barcenas, Richard J Bleicher, Adam L Cohen, Sara H Javid, Ellis G Levine, Nancy U Lin, Beverly Moy, Joyce C Niland, Antonio C Wolff, Michael J ...> ;Breast. 2023 Feb 1
• 2 citations
  A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN).
  Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie L Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo,...> ;NPJ Breast Cancer. 2023 Jan 6
• 4 citations
  Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.
  Erik S Knudsen, Emily Schultz, Deanna Hamilton, Kris Attwood, Stephen Edge, Tracey O'Connor, Ellis Levine, Agnieszka K Witkiewicz> ;The Oncologist. 2022 Aug 5
• 15 citations
  Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
  Neeraj Agarwal, Catherine M Tangen, Maha H A Hussain, Shilpa Gupta, Melissa Plets, Primo N Lara, Andrea L Harzstark, Przemyslaw W Twardowski, Channing J Paller, Dylan ...> ;Journal of Clinical Oncology. 2022 Oct 1
• 2 citations
  Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
  Maithreyi Sarma, Stuthi Perimbeti, Samar Nasir, Kristopher Attwood, Ankita Kapoor, Tracey O'Connor, Amy Early, Ellis G Levine, Kazuaki Takabe, Pawel Kalinski, Christin...> ;Breast Cancer Research and Treatment. 2022 Apr 1
• A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
  Voorhees PM, Suman VJ, Tuchman SA, Laubach JP, Hassoun H, Efebera YA, Mulkey F, Bova-Solem M, Santo K, Carlisle D, McCarthy PL, Richardson PG> ;American journal of hematology. 2021-10-06
• Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
  Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH, Mattison RJ, Storrick E, Christner SM, Lewis LD, Devine S, Stone RM, Larson RA> ;Blood advances.
• 4 citations
  Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience.
  Sabah Alaklabi, Arya Mariam Roy, Kristopher Attwood, Anthony George, Tracey O'Connor, Amy Early, Ellis G Levine, Shipra Gandhi> ;Frontiers in Oncology. 2022 Jan 1
• 41 citations
  E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer...
  Roisin M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown-Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. O...> ;Journal of Clinical Oncology. 2021 Aug 6
• 9 citations
  CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.
  Jennifer K Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Javier G. Blanco, Tracey O'Connor> ;Cardio-Oncology. 2021 May 11
• 11 citations
  Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study
  Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nan Lin, Beverly Moy, Joyce C. Niland, Antonio C. Wolff, Michael J....> ;Journal of the National Comprehensive Cancer Network. 2021 Mar 10
• 22 citations
  Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib.
  Ajay Dhakal, Roby Antony Thomas, Ellis G. Levine, Adam Brufsky, Kazuaki Takabe, Matthew G. Hanna, Kristopher Attwood, Austin Miller, Thaer Khoury, Amy P. Early, Saif S...> ;Breast Cancer. 2020 Jul 23
• 36 citations
  MammaPrint guides treatment decisions in breast cancer: results of the IMPACt trial.
  Hatem Soliman, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis G. Levine, B Mavromatis, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Klin...> ;BMC Cancer. 2020 Jan 31
• 271 citations
  Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
  Timothy D Gilligan, Daniel W. Lin, Rahul Aggarwal, David D. Chism, Nicholas G. Cost, Ithaar Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L...> ;Journal of the National Comprehensive Cancer Network. 2019 Dec 1
• 18 citations
  Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment
  Ajay Dhakal, Christina Matthews, Ellis G. Levine, Kilian E. Salerno, Fan Zhang, Kazuaki Takabe, Amy P. Early, Stephen B. Edge, Tracy O'Connor, Thaer Khoury, Jessica Yo...> ;Clinical Breast Cancer. 2018 Apr 28
• 32 citations
  Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gen...
  Michaela Tsai, Shelly S. Lo, William Audeh, Rubina Qamar, Raye Budway, Ellis G. Levine, Pat Whitworth, B Mavromatis, Robin Zon, Dwight Oldham, Sarah Untch, Tina Treece...> ;JAMA Oncology. 2018 Jan 11
• 18 citations
  Impact of suboptimal neoadjuvant chemotherapy on peri‐operative outcomes and survival after robot‐assisted radical cystectomy: a multicentre multinational study
  Nobuyuki Hinata, Ahmed A. Hussein, Saby George, Donald L. Trump, Ellis G. Levine, Kawa Omar, Prokar Dasgupta, Muhammad Shamim Khan, Abolfazl Hosseini, Peter Wiklund, K...> ;BJU International. 2017 Apr 1
• 23 citations
  Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitor...
  Kerin B. Adelson, Bhuvaneswari Ramaswamy, Joseph A. Sparano, Paul J. Christos, John J. Wright, George Raptis, Gang Han, Miguel A. Villalona-Calero, Cynthia X. Ma, Dawn...> ;NPJ Breast Cancer. 2016 Dec 14
• 25 citations
  A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
  Steven A. Limentani, Mario Campone, Thierry Dorval, Giuseppe Curigliano, Richard De Boer, Charles L. Vogel, Shane White, Thomas Bachelot, Jean-Luc Canon, Mary L. Disis...> ;Breast Cancer Research and Treatment. 2016 Mar 18
• 48 citations
  Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
  Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn N. Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron S. Czuczman, Matthew S. Davids, Ellis G. Le...> ;Blood. 2015 Dec 3
• 79 citations
  Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology
  Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair J. Beard, Sam B. Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, S...> ;Journal of the National Comprehensive Cancer Network. 2015 Jun 1
• 206 citations
  Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines
  Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair J. Beard, Sam B. Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, S...> ;Journal of the National Comprehensive Cancer Network. 2015 Feb 1
• Join now to see all

Journal Articles

• Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study  
  Denysschen CA, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O’Connor T, Eur J Cancer Care, 1/1/2014
• A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma  
  Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radke AO, Puzanov I, MacVicar GR, Levine EG, Srivivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN,..., Cancer, 1/1/2014
• Kidney cancer, version 22014  
  Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolgr GB, Chang SS, Choueriri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, L..., J Natl Compr Canc Netw, 1/1/2014
• Time-trends in survival in young women with breast cancer in a SEER population-based study  
  Ademuyiwa FO, Groman A, Hong CC, Miller A, Kumar S, Levine E, Erwin D, Ambrosome C, Breast Cancer Res Treat, 1/1/2013
• Understanding avoidance, refusal and abandonment of chemotherapy before and after cystectomy for bladder cancer  
  Rehman S, Crane A, Stegemann AP, Din R, Shi Y, Wilding G, Levine EG, George S, Trump DL, Guru KA, Urology, 1/1/2013
• Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis  
  Ngamphaiboon N, O’Connor TL, Advani PP, Levine EG, Kossoff EB, Med Oncol, 1/1/2012
• The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort  
  Ademuyiwa FO, Miller A, O’Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S, Breast Cancer Res Treat, 1/1/2011
• Phase II trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration resistant prostate cancer  
  Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump D, Cancer, 1/1/2010
• Length of survival in Hospice for cancer patients referred from a comprehensive cancer center  
  Younis T, Milch R, Abul-Khoudoud N, Lawrence D, Mirand A, Levine E, Am J Hospice and Palliative Medicine, 1/1/2009
• NCCN clinical practice guidelines in oncology: testicular cancer  
  Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Chhoueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR Jonasch E, Kessinger A, Kuzel TM, Lange PH, L..., J Natl Compr Canc Netw, 1/1/2009
• A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer  
  O’Connor T, Rustum Y, Levine E, Creaven P, Cancer Chemotherapy and Pharmacology, 1/1/2008
• What did you think of the hematology/oncology rotation? A survey of Internal Medicine Residents  
  Chen H, Mortazavi A, Levine E, Kamisetti S, Kamisetti S, Ramnath N, Journal of Cancer Education, 1/1/2007
• Kidney cancer Clinical practice guidelines in oncology  
  Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margollin KA..., J Natl Compr Canc Netw, 1/1/2006
• HER-2/neu evaluation in breast cancer Pathology Patterns Reviews  
  Winston JS, Ramanarayan J, Levine EG, Am J Clin Pathol, 1/1/2004
• Barriers to clinical trial participation by older women with breast cancer  
  Kemeny MM, Peterson B, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ, J Clin Oncol, 1/1/2003
• Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids  
  Kawinski E, Levine E, Chadha K, The Prostate, 1/1/2002
• Is MUGA scan necessary in low-risk breast cancer patients prior to doxorubicin-based adjuvant therapy  
  Sabel MS, Levine EG, Hurd T, Schwartz GN, Zielinski R, Hohn D, Edge SB, Am J Clin Oncol, 1/1/2001
• Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer  
  Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Stadler W, J Clin Oncol, 1/1/2000
• Phase II trial of topotecan in advanced breast cancer: A Cancer and Leukemia Group B Study  
  Levine E, Cirrincione CT, Szatrowski TP, Canellos G, Norton L, Henderson, IC, American Journal of Clinical Oncology, 1/1/1999
• Flow cytometric DNA analysis of invasive carcinomas detected by screening mammography: Use of specimen mammography-guided fine needle aspirates  
  Stomper, PC, DeBloom JR, Levine E, Budnick RM, Stewart CC, Clinical Cancer Research, 1/1/1998
• Unusual central nervous system toxicity in a phase I study of N1N11Diethylnorspermine in patients with advanced malignancy  
  Creaven PJ, Perez R, Pendyala L, Meropol N, Loewen G, Levine E, Berghorn E, Raghavan D, Invest New Drugs, 1/1/1997
• Therapy for inflammatory breast cancer: Impact of doxorubicin-based therapy  
  Bauer, RL. Busch E,. Levine E, Edge SB, Annals of Surgical Oncology, 1/1/1995
• Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen  
  Creaven PJ, Rustum YM, Petrelli NJ, Meropol NJ, Raghavan D, Rodriguez-Bigas M, Levine EG, Frank C, Udvary-Nagy S, Proefrock A, Cancer Chemother Pharmacol, 1/1/1994
• MVAC for bladder cancer: Time to move forward again  
  Levine E, Raghavan D, Journal of Clinical Oncology, 1/1/1993
• Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure  
  Levine EG, Bloomfield CD, Seminars in Oncology, 1/1/1992
• Join now to see all

Books/Book Chapters

• Textbook of Uncommon Cancer 
  Chapter: Sarcomas of the adult prostate gland 
  Levine, EG, Gaeta JF, Huben RF:Editors: Raghavan D, Brecher M, Johnson DH, Meropol NJ, Thigpen JY.John Wiley & Sons, Ltd., Sussex, England1999
• Principles and Practice of Genitourinary Oncology 
  Chapter: Genitourinary sarcomas 
  Levine EG, Brooks JSJ, Spellman J, Velagapudi SEditors: Raghavan D, Scher HI, Leibel SA, Lange PH.J.B. Lippincott Company, Philadelphia, PA1997
• Cancer Patient Follow-up: Surveillance Strategies After Primary Treatment of Cancer 
  Chapter: Breast carcinoma 
  Edge SB, Levine EG, Arredondo MA, Tezcan HEditors: Johnson FE, Virgo KS.Mosby-Year Book, Inc., St. Louis1997
• Medical Oncology 
  Chapter: Leukemias 
  Bloomfield CD, Foon KA, Levine EGEditors: Calabresi P, Schein PS.McGraw Hill, Inc., New York, NY1993
• Neoplastic Diseases of the Blood 
  Chapter: Cytogenetics of malignant lymphoma 
  Levine EG, Bloomfield CDEditors: Wiernik PH, Canellos GP, Kyle RA, Schiffer CA.Churchill Livingstone, New York, NY1991
• Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances 
  Chapter: Banded chromosome abnormalities in non-Hodgkin's lymphoma. Correlations with morphology, immunologic phenotype and clinical course 
  Bloomfield CD, Arthur DC, Levine EG, Frizzera G, Gajl-Peczalska KJ, LeBien TW, Hurd DD, Peterson BAEditors: Cavalli F, Bonadonna G, Rozencweig M.Martinus Nijhoff Publishers, Hingham, MA1985
• Join now to see all

Abstracts/Posters

• Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC)
  Pokuri VK, Syed JR, Yang Z, Field EP, Pili R, Levine EG, Trump DL, Hutson A, Guru K, George S, Proc Am Soc Clin Oncol, 1/1/2014
• Secondary breast cancer following hematologic malignancies
  Tanveer F, Ford LA, Wang ES, Levine EG, O’Connor TL, Wetzler M, Proc Am Soc Clin Oncol, 1/1/2014
• A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or ...
  Levine EG, Forero A, O’Connor T, Seon BK, Jivani MA, Adams BJ, Theuer CP, Proc Am Soc Clin Oncol, 1/1/2013
• Tolerability and cardiac safety of neo/adjuvant trastuzumab-based chemotherapy regimens for HER2+ breast cancer: A single institution experience
  Jitawatanarat P, Kossoff E, Riebandt G, Levine EG, O’Connor TL, Chittawatanarat K, Ngamphaiboon N, Proc Am Soc Clin Oncol, 1/1/2013
• A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy
  Kotowski AS, Stegemann A, Rehman S, Attwood K, Levine EG, Guru K, Trump DL, Pili R, J Clin Oncol and ASCO Genitourinary Cancer Symposium, 2/1/2012
• Factors affecting delivery of planned neoadjuvant/adjuvant chemotherapy for breast cancer in older women
  Ngamphaiboon N, Edge SB, Groman A, Kossoff EB, Wilding GE, Ademuyiwa F, Levine EG, Watroba N, O’Connor TL, San Antonio Breast Cancer Symposium, 12/1/2011
• A long journey from target discovery to clinical application: Discovery of endoglin and development of chimeric anti-endoglin antibody for targeting tumor vasculature...
  Seon BK, Haba A, Harada N, Tsujie M, Toi H, Tsai J, Duzen K, Fukita DA, Mendelson LS, Rosen JW, Goldman JW, Gordon MS, Hurwitz H, Wong M, Levine E, Adams BJ, Theuer CP..., 2011 Era of Hope Meeting, 8/1/2011
• Phase II trial of neoadjuvant pegylated liposomal doxorubicin with paclitaxel and trastuzumab in patients with operable Her-2 positive breast cancer
  Hymans DM, Leichman GC, Klein P, Reitchsel P, Levine EG, Gelski VJ. Kelley MA, Cancer Research and San Antonio Breast Cancer Symposium, 12/1/2009
• Length of survival (LOS) of cancer patients in hospice and prior enrollment in phase I studies
  Younis T, Milch R, Abul-Khoudoud N, Lawrence D, Mirand A. Walsh D, and Levine EG, Proc Am Soc Clin Oncol, 1/1/2004
• A model for predicting progression free survival in men with hormone refractory prostate cancer (HRPC): An analysis of CALGB studies
  Halabi S, Small E, Kattan M, Kantoff P, Dawson N, Levine E, Oh W, Kaplan E, Vogelzang N, Proc Am Soc Clin Oncol, 1/1/2003
• Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG 8814)
  Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S, Osborne CK, Proc Am Soc Clin Oncol, 1/1/2002
• A model for predicting survival in men with hormone refractory prostate cancer (HRCaP): An analysis of CALGB studies
  Halabi S, Small EJ, Kantoff PW, Dawson NA, Levine EG, Vogelzang NJ, Proc Am Soc Clin Oncol, 1/1/2002
• Overall survival after cyclophosphamide, Adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor (+), node (+) breast cancer: New fi...
  Albain K, Green S, Ravdin P, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M, Norton L, Lew D, Martino S, Osborne K, Proc Am Soc Clin Oncol, 1/1/2001
• Phase I trial of recombinant human anti-Her2 monoclonal antibody (H) plus low-dose interleukin-2 (IL-2) in patients with solid tumors
  Fleming GF, Meropol NJ, Hollis DR, Rosner GL, Fracasso PM, Sosman JA, Tkaczuk L, Levine EG, Rhoades C, Caligiuri MA, Carson WE, Ratain MJ, Proceedings of the American Society of Clinical Oncology, 1/1/1999
• Preliminary results of CALGB 9680: A phase II trial of high dose mitoxantrone/GM-CSF and low dose steroids in hormone refractory prostate cancer (HRPC)
  Levine EG, Halabi S, Hars V, Rago R, Vogelzang NJ, Proceedings of the American Society of Clinical Oncology, 1/1/1998
• Tamoxifen (T) vs. Cyclophosphamide, Adriamycin, and 5-FU (CAF) pluse either concurrent or sequential T in postmenopausal receptor (+), node (+) breast cancer: A South...
  Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, O'Sullivan J, Hess E, Martino S, Proceedings of the American Society of Clinical Oncology, 1/1/1997
• Practice guidelines in breast cancer: Guideline variations in a comprehensive cancer center
  Edge SB, Watroba N, Arredondo MA, Carson WC, Levine E, Schwartz G, Kim S, Breast Cancer Research and Treatment, 1/1/1996
• A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma
  Stadler W, Kuzel T, Raghavan D, Levine E, Vogelzang N, Dorr FA, Proceedings of the American Society of Clinical Oncology, 1/1/1995
• Minimum 6 year follow-up of 133 patients (PTS) aged >70 years treated for breast cancer (CAB)
  Villalona-Calero M, Budnick R, Levine E, Walsh D, Stewart C, Penetrante R, Tsangaris T, Raghavan D, Proceedings of the American Society of Clinical Oncology, 1/1/1993
• Phase I clinical trial of floxuridine (FUdR) with leucovorin (LV) in patients (PTS) with advanced genitourinary cancer (AGC)
  Raminski D, Creaven PJ, Rustum YM, Perrapato S, Huben R, Levine E, Berghorn E, Proceedings of the American Society of Clinical Oncology, 1/1/1992
• Cytogenetic heterogeneity of true histiocytic lymphoma
  Dohner H, Frizzera G , Levine E, Griesinger F, Jaszcz W, Peterson BA, Arthur DC, Blood, 1/1/1990
• Autologous transplantation (TXN) in Hodgkin's disease (HD) using bone marrow (BMSC) or peripheral blood (PBSC) derived stem cells
  Hurd D, Lasky L, Haake R, Peterson B, Kim T, Christiansen N, Weisdorf D, Bostrom B, Levine E, McGlave P, Bloomfield C, Proceedings of the American Society of Clinical Oncology, 1/1/1988
• Recurring chromosome translocations in B-cell malignant lymphoma
  Bloomfield CD, Levine EG, Machnicki J, Frizzera G, Gajl-Peczalska KJ, Arthur DC, Ninth International Human Gene Mapping Workshop and Cytogenet Cell Genet, 1/1/1987
• Cytogenetic analysis in lymphomas predicts survival
  Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, and Bloomfield CD, Education Booklet of the LSA Medical Conference: Second National Symposium, 1/1/1986
• Prognostic significance of cytogenetic abnormalities in non-Hodgkin's lymphoma
  Levine EG, Arthur DC, Frizzera G, Peterson BA, Hurd DD, and Bloomfield CD, Blood, 1/1/1986
• Join now to see all

Lectures

• The Evaluation System has Changed: Introduction to the Milestones 
  Roswell Park Cancer Institute, Buffalo, NY - 8/12/2014
• Managing Treatments’s Side Effects in Advanced Prostate Cancer 
  Buffalo, NY - 8/24/2012
• Breast Cancer - When to Treat and What to Use? 
  Buffalo, NY - 10/16/2010
• Breast Cancer 
  Buffalo, NY - 7/15/2006
• Drugs Commonly Used in Breast Cancer 
  Hyatt Regency, Buffalo, NY - 10/29/2004
• Systemic Issues in Breast Cancer 
  Buffalo, NY - 4/7/2004
• Hot Topics at ASCO 
  Roswell Park Cancer Institute, Buffalo, NY - 6/14/2003
• Adjuvant Chemotherapy and Tamoxifen Treatment: Which Patients Benefit? 
  Buffalo, NY - 3/9/2002
• Update Across the Disciplines on the Prevention and Treatment of Breast Cancer 
  Buffalo, NY - 11/4/2000
• Ethics of Clinical Trials 
  Buffalo, NY - 11/3/1999
• Breast Cancer: Preservation of the Breast 
  Buffalo, NY - 10/29/1998
• Adjuvant Treatment of Localized Breast Cancer-New Approaches 
  Buffalo, NY - 5/14/1998
• Clinical Trials Offered to Women with Breast Cancer at RPCI 
  East Aurora, NY - 5/14/1997
• Principles of solid tumor chemotherapy 
  Buffalo, NY - 12/18/1996
• How to be a study chair 
  Miami Beach, FL - 5/4/1996
• Peripheral primitive neuroectodermal tumors in adults 
  Buffalo, NY - 4/19/1996
• Advanced breast cancer: What have we learned from clinical trials? 
  Buffalo, NY - 10/6/1995
• Residual disease following cytoreductive chemotherapy of testicular cancer 
  Buffalo, NY - 10/14/1994
• Outpatient approaches to cancer medicine 
  Millard Fillmore Hospital, Buffalo, NY - 11/15/1990
• Recent progress in genitourinary malignancies 
  1/17/1990
• Chemotherapeutic approach to testis cancer 
  10/7/1989
• Follicular lymphoma as a paradigm for new treatment approaches in cancer medicine 
  5/4/1989
• Cytogenetic correlates in the non-Hodgkin's lymphomas 
  Buffalo, NY - 2/16/1989
• Follicular lymphomas: Where have we been? Where should we go? 
  Atlanta, GA - 10/27/1988
• Current concepts in the genetics of common cancers 
  2/21/1987
• Join now to see all